US prevalence
~30% of US adults (HOMA-IR-based estimate)
Source: Multiple cohorts
Loading content…
Condition
Insulin Resistance
Reduced cellular response to insulin, a precursor to type 2 diabetes. GLP-1 therapy improves insulin sensitivity via weight loss and incretin effects, but no GLP-1 carries a standalone indication. There is no FDA indication for insulin resistance as a standalone diagnosis — it is a physiological state, not a labeled disease. GLP-1 therapy improves insulin sensitivity through weight loss, slowed gastric emptying, glucagon suppression, and beta-cell function preservation. Evidence grade: B. Patients with insulin resistance are typically treated via comorbid diagnoses (obesity, prediabetes, PCOS, T2D). HOMA-IR scores typically improve 30-50% with sustained semaglutide or tirzepatide therapy.
Quick answer
UpdatedInsulin resistance is the precursor to type 2 diabetes and metabolic syndrome — cells become less responsive to insulin, requiring higher insulin levels to maintain normal glucose. Estimated 1 in 3 US adults has some degree of insulin resistance. GLP-1 medications improve insulin sensitivity through multiple mechanisms: weight loss, direct effects on insulin signaling pathways, and improved beta-cell function. Not FDA-approved specifically for insulin resistance.
- US prevalence: ~30% of adults (estimated)
- Difficult to measure precisely; HOMA-IR-based estimates
- T2D progression risk: ~3-7% annually in insulin-resistant patients
- Depends on additional factors (obesity, family history)
- Diagnostic criteria: HOMA-IR >2.5 or fasting insulin >25
- No universal standard
- First-line therapy: Lifestyle modification (diet + exercise + weight loss)
- Metformin for at-risk patients
- GLP-1 mechanism: Improves insulin sensitivity via weight loss + direct signaling
- Off-label in insulin resistance + obesity